Patent: 6,290,961
✉ Email this page to a colleague
Summary for Patent: 6,290,961
Title: | Method for treating dystonia with botulinum toxin type B |
Abstract: | A method and composition for treating a patient, suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G. |
Inventor(s): | Aoki; K. Roger (Laguna Hill, CA), Grayston; Michael W. (Irvine, CA), Carlson; Steven R. (Laguna Niguel, CA), Leon; Judith M. (Laguna Niguel, CA) |
Assignee: | Allergan, Inc. (Irvine, CA) |
Application Number: | 09/490,756 |
Patent Claims: | see list of patent claims |
Details for Patent 6,290,961
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Solstice Neurosciences, Llc | MYOBLOC | rimabotulinumtoxinb | Injection | 103846 | 12/08/2000 | ⤷ Try a Trial | 2013-12-28 |
Genzyme Corporation | CAMPATH | alemtuzumab | Injection | 103948 | 05/07/2001 | ⤷ Try a Trial | 2013-12-28 |
Genzyme Corporation | LEMTRADA | alemtuzumab | Injection | 103948 | 11/14/2014 | ⤷ Try a Trial | 2013-12-28 |
Genzyme Corporation | CAMPATH | alemtuzumab | Injection | 103948 | 10/12/2004 | ⤷ Try a Trial | 2013-12-28 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 6,290,961
Country | Patent Number | Estimated Expiration |
---|---|---|
World Intellectual Property Organization (WIPO) | 9517904 | ⤷ Try a Trial |
United States of America | 8557256 | ⤷ Try a Trial |
United States of America | 8486886 | ⤷ Try a Trial |
United States of America | 8216995 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |